Treatment of Sepsis-related Acute Respiratory Distress Syndrome with Vasoactive Intestinal Peptide-Reference-Cited by-同舟云学术

Treatment of Sepsis-related Acute Respiratory Distress Syndrome with Vasoactive Intestinal Peptide

Published:2020 Issue: Volume: Page:
ISSN:1556-5068
Container-title:SSRN Electronic Journal
language:en
Short-container-title:SSRN Journal

Author:

Said Sami,Youssef George,Javitt Matthew J.,Javitt Jonathan

Publisher

Elsevier BV

Reference23 articles.

1. Acute respiratory distress syndrome-attributable mortality in critically ill patients with sepsis;C L Auriemma;Intensive Care Med,2020

2. Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries;G Bellani;JAMA,2016

3. Immunohistochemical localization and distribution of VIP/PACAP receptors in human lung;R Busto;Peptides,2000

4. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6;M Delgado;J Immunol,1999

5. Vagal nerve stimulation releases vasoactive intestinal peptide which significantly increases coronary artery blood flow;L Feliciano;Cardiovasc Res,1998

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aviptadil: Class Effect of a Synthetic Vasoactive Intestinal Peptide as a Treatment Option in Patients with COVID-19 with Severe Respiratory Failure;EMJ Microbiology & Infectious Diseases;2022-01-10

2. Increased Recovery and Survival in Patients With COVID-19 Respiratory Failure Following Treatment with Aviptadil: Report #1 of the ZYESAMI COVID-19 Research Group;SSRN Electronic Journal;2021

3. Rapid Recovery from COVID-19 Respiratory Failure after treatment with Vasoactive Intestinal Peptide;SSRN Electronic Journal;2020